Hepatitis C
Conditions
Keywords
Hepatitis C Nonresponder, Genotype 1, Interferon Alfacon-1, Consensus Interferon, CIFN, Infergen, Ribavirin
Brief summary
The main purpose of this study is to evaluate the safety and tolerability of combination therapy of daily interferon alfacon-1 (Infergen, CIFN) at high dosage (24 mcg) with ribavirin (based on body weight) for 48 weeks in HCV genotype 1 infected subjects, who are non-responders to previous pegylated interferon alfa plus ribavirin therapy. This is an open-label, multicenter study. All subjects will receive Infergen 24 mcg administered by injection daily plus ribavirin 800-1400 mg (based on body weight) administered by mouth daily for 48 weeks \* If any 5 of the first 10 subjects can not tolerate the 24 mcg daily dosage of Infergen by week 4, as determined by the principal investigator, then the dosage of Infergen will be changed to 15 mcg administered by injection daily plus ribavirin 800-1400 mg (based on body weight) administered by mouth daily for 48 weeks
Interventions
DRUGInterferon Alfacon-1 and Ribavirin
Sponsors
InterMune
Beth Israel Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Must have documented failure to respond to past treatment with a Pegylated IFN + RBV. Failure to respond to past treatment is defined as positive HCV RNA at 12 weeks and less than a 2 log drop from baseline; OR positive HCV RNA and greater than 2 log drop from baseline at week 12 and must have received 24 weeks of therapy and still have a positive HCV RNA * Must have tolerated previous hepatitis C therapy * Must be off hepatitis C therapy for 3 months prior to study participation * Must have had a liver biopsy within the past 5 years
Exclusion criteria
* Decompensated liver disease * Laboratory abnormalities as per protocol * HIV+ * Autoimmune disease * Unstable or deteriorating cardiovascular or cerebrovascular disease * History of seizures in past 5 years * Alcohol or drug abuse in past year * Pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| *Assessment of safety and tolerability of high dosage Infergen plus ribavirin including adverse events;study medication dose reduction, interruptions, and discontinuations; and BDI-II scores | — |
Secondary
| Measure | Time frame |
|---|---|
| *Sustained viral response defined as the absence of detectable HCV RNA at week 72 | — |
Countries
United States
Outcome results
None listed